Back to top
more

Affimed (AFMD)

(Delayed Data from NSDQ)

$4.39 USD

4.39
78,830

+0.04 (0.92%)

Updated Aug 7, 2024 04:00 PM ET

After-Market: $4.38 -0.01 (-0.23%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?

by Zacks Equity Research

An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.

UnitedHealth (UNH) to Post Q4 Earnings: What You Should Know

by Zacks Equity Research

UnitedHealth Group's (UNH) fourth-quarter results are likely to reflect growing premiums, products and higher expenses.

Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

by Zacks Equity Research

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 21.15% and 44.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 5.13% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View

by Zacks Equity Research

Centene (CNC) currently has $3.4 billion remaining in its share buyback program.

Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.

UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?

by Zacks Equity Research

UnitedHealth Group's (UNH) second-quarter results are likely to reflect improving premiums, products and higher expenses.

Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq

by Zacks Equity Research

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.